Trends in pneumococcal meningitis hospitalizations following the introduction of the 13-valent pneumococcal conjugate vaccine in the United States

•Rates of pneumococcal meningitis decreased following introduction of PCV13 vaccine.•Rates of non-pneumococcal meningitis also decreased in the U.S. from 2008–2014.•No change in case fatality rate in patients with PM over this time period. The 13-valent pneumococcal conjugate vaccine (PCV13) was int...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2017-10, Vol.35 (45), p.6160-6165
Main Authors: Jacobs, David M., Yung, Francine, Hart, Emily, Nguyen, Melanie N.H., Shaver, Amy
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Censuses
Child
Child, Preschool
Children
Conjugate vaccine
Epidemiology
Fatalities
Female
Hospitalization - trends
Humans
Immunization
Incidence
Inpatients - statistics & numerical data
International Classification of Diseases - statistics & numerical data
Male
Meningitis
Meningitis, Pneumococcal - immunology
Meningitis, Pneumococcal - prevention & control
Middle Aged
Mortality
Pneumococcal Vaccines - immunology
Retrospective Studies
Staphylococcus aureus
Streptococcus infections
Streptococcus pneumoniae
Trends
United States
Vaccines
Vaccines, Conjugate - immunology
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Rates of pneumococcal meningitis decreased following introduction of PCV13 vaccine.•Rates of non-pneumococcal meningitis also decreased in the U.S. from 2008–2014.•No change in case fatality rate in patients with PM over this time period. The 13-valent pneumococcal conjugate vaccine (PCV13) was introduced in 2010 in the U.S. and its impact on pneumococcal meningitis (PM) is unknown. We assessed the impact of PCV13 on PM hospitalization rates 4years after the vaccine was introduced. This was a retrospective analysis of the National Inpatient Sample from 2008–2014. Patients with an ICD-9-CM code for PM (320.1) were identified and rates calculated using US Census data as the denominator. Data weights were used to derive national estimates. We examined three time periods: 2008–2009 (late post-PCV7), 2010 (transition year), and 2011–2014 (post-PCV13). During the study period, there were 10,493 hospitalizations due to PM in the U.S. Overall, PM incidence decreased from 0.62 to 0.38 cases per 100,000 over this time (39% decrease; P
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2017.09.050